Labcorp Holdings, Inc. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1294026,
    "name": "Labcorp Holdings, Inc.",
    "stock_name": "Labcorp Holdings, Inc.",
    "full_name": "Labcorp Holdings, Inc.",
    "name_url": "stocks-analysis/labcorp-holdings-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "258.39",
    "chg": -3.09,
    "chgp": "-1.18%",
    "dir": -1,
    "prev_price": "261.48",
    "mcapval": "23,036.15",
    "mcap": "Mid Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 3365,
    "indexname": "S&P 500",
    "isin": "US5049221055",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "421.67 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/labcorp-holdings-inc-1294026-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Labcorp Holdings, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-labcorp-holdings-inc-overvalued-or-undervalued-3638060",
        "imagepath": "",
        "date": "2025-10-21 12:14:28",
        "description": "As of 17 October 2025, the valuation grade for Labcorp Holdings, Inc. has moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 28.86, an EV to EBITDA of 14.80, and a PEG ratio of 0.0. In comparison, peers in the Pharmaceuticals & Biotechnology industry exhibit varying valuations, with notable competitors having different P/E ratios that reflect their market positions.\n\nIn terms of performance, Labcorp has demonstrated strong returns, with a year-to-date return of 24.69% compared to the S&P 500's 13.30%, and a one-year return of 32.91% versus the S&P 500's 14.08%. This performance indicates that while Labcorp is fairly valued, it has outperformed the broader market over multiple periods, reinforcing its competitive position within the industry...."
      },
      {
        "title": "Labcorp Holdings Experiences Valuation Adjustment Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/labcorp-holdings-changes-valuation-grade-from-expensive-to-fair-amid-price-increase-3641226",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/LabcorpHoldings_valuationdot_3641226.png",
        "date": "2025-10-20 17:48:09",
        "description": "Labcorp Holdings, Inc. has recently adjusted its valuation, with its current price at $285.94. The company has shown strong performance over the past year, achieving a 32.91% return, significantly outperforming the S&P 500. Key financial metrics indicate Labcorp's competitive positioning within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Labcorp Holdings, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/labcorp-holdings-inc-technical-trend-upgrades-from-mildly-bullish-to-bullish-amid-strong-performance-3640526",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/LabcorpHoldings_technicaldot_3640526.png",
        "date": "2025-10-20 15:34:51",
        "description": "Labcorp Holdings, Inc. has recently revised its evaluation amid current market dynamics. The stock has shown strong performance over the past year, significantly outperforming the S&P 500. Technical indicators present mixed signals, with bullish trends in some areas and bearish indicators in others, reflecting a complex market environment."
      },
      {
        "title": "Is Labcorp Holdings, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-labcorp-holdings-inc-overvalued-or-undervalued-3634932",
        "imagepath": "",
        "date": "2025-10-20 12:31:46",
        "description": "As of 17 October 2025, the valuation grade for Labcorp Holdings, Inc. has moved from expensive to fair. The company is currently fairly valued based on its metrics. Key ratios include a P/E ratio of 28.86, an EV to EBITDA of 14.80, and a PEG ratio of 0.0, indicating a lack of growth expectations priced into the stock.\n\nIn comparison to peers, Labcorp's P/E ratio is notably higher than the industry average, suggesting that it is priced at a premium relative to its competitors. For instance, if we consider other companies in the Pharmaceuticals & Biotechnology sector, their P/E ratios may provide a clearer picture of relative valuation. Additionally, Labcorp has outperformed the S&P 500 over multiple periods, with a year-to-date return of 24.69% compared to the S&P 500's 13.30%, reinforcing the narrative of its fair valuation amidst strong performance...."
      },
      {
        "title": "Is Labcorp Holdings, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-labcorp-holdings-inc-overvalued-or-undervalued-3632464",
        "imagepath": "",
        "date": "2025-10-19 12:08:45",
        "description": "As of 17 October 2025, the valuation grade for Labcorp Holdings, Inc. moved from expensive to fair. The company is currently fairly valued based on its metrics. Key ratios include a P/E ratio of 28.86, an EV to EBITDA of 14.80, and a PEG ratio of 0.0, indicating a lack of growth expectations priced into the stock. In comparison, peers such as Thermo Fisher Scientific have a P/E of 24.50, suggesting Labcorp's valuation is in line with industry standards.\n\nLabcorp has outperformed the S&P 500 with a year-to-date return of 24.69% compared to the S&P 500's 13.30%, reinforcing the notion that the stock is fairly valued given its recent performance...."
      },
      {
        "title": "Labcorp Holdings Hits New 52-Week High of $289.19",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/labcorp-holdings-hits-new-52-week-high-of-28919-3588446",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/LabcorpHoldings_priceRelatedfactors_3588446.png",
        "date": "2025-10-02 22:45:41",
        "description": "Labcorp Holdings, Inc. achieved a new 52-week high of USD 289.19 on October 1, 2025, highlighting its strong position in the Pharmaceuticals & Biotechnology industry. The company has outperformed the S&P 500 over the past year, reflecting significant market momentum and robust financial metrics."
      },
      {
        "title": "Labcorp Holdings Hits New 52-Week High at $288.24",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/labcorp-holdings-hits-new-52-week-high-at-28824-3586110",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/LabcorpHoldings_priceRelatedfactors_3586110.png",
        "date": "2025-10-01 16:49:03",
        "description": "Labcorp Holdings, Inc. achieved a new 52-week high of USD 288.24 on September 30, 2025, highlighting its strong position in the Pharmaceuticals & Biotechnology sector. The company has shown resilience over the past year, with significant stock performance and ongoing engagement in the competitive market landscape."
      },
      {
        "title": "Is Labcorp Holdings, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-labcorp-holdings-inc-technically-bullish-or-bearish-3549108",
        "imagepath": "",
        "date": "2025-09-20 20:32:53",
        "description": "As of 1 October 2023, the technical stance for Labcorp Holdings, Inc. is bullish overall, with a strong bullish signal from the MACD on both weekly and monthly time frames. The daily moving averages also indicate bullish momentum. Additionally, the Bollinger Bands and OBV show mildly bullish trends on both weekly and monthly periods. However, Dow Theory suggests a mildly bearish stance on the monthly timeframe, indicating some caution. \n\nIn terms of performance, Labcorp has outperformed the S&P 500 year-to-date with a return of 20.86% compared to the S&P 500's 12.22%, and over the past year, it has also outperformed with a return of 21.97% versus 17.14%. Overall, the bullish indicators suggest a positive outlook despite some mixed signals in the longer-term trends...."
      },
      {
        "title": "Is Labcorp Holdings, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-labcorp-holdings-inc-overvalued-or-undervalued-3544609",
        "imagepath": "",
        "date": "2025-09-20 18:50:37",
        "description": "As of 6 February 2025, the valuation grade for Labcorp Holdings, Inc. has moved from expensive to fair, indicating a more favorable assessment of its market position. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 28.86, an EV/EBITDA of 14.80, and a PEG ratio of 0.0. In comparison, its peers in the Pharmaceuticals & Biotechnology industry exhibit varying valuations, but Labcorp's P/E ratio aligns closely with industry standards, suggesting it is competitively positioned.\n\nIn terms of recent performance, Labcorp has outperformed the S&P 500 year-to-date with a return of 20.86% compared to the index's 12.22%, although it lags behind the S&P 500 over longer periods, such as the last three and five years. This mixed performance reinforces the notion that while the company is currently fairly valued, its long-term growth may need to be closely monitored against broader ..."
      }
    ],
    "total": 9,
    "sid": "1294026",
    "stock_news_url": "https://www.marketsmojo.com/news/labcorp-holdings-inc-1294026"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Labcorp Holdings, Inc. overvalued or undervalued?

2025-10-21 12:14:28

As of 17 October 2025, the valuation grade for Labcorp Holdings, Inc. has moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 28.86, an EV to EBITDA of 14.80, and a PEG ratio of 0.0. In comparison, peers in the Pharmaceuticals & Biotechnology industry exhibit varying valuations, with notable competitors having different P/E ratios that reflect their market positions. In terms of performance, Labcorp has demonstrated strong returns, with a year-to-date return of 24.69% compared to the S&P 500's 13.30%, and a one-year return of 32.91% versus the S&P 500's 14.08%. This performance indicates that while Labcorp is fairly valued, it has outperformed the broader market over multiple periods, reinforcing its competitive position within the industry....

Labcorp Holdings Experiences Valuation Adjustment Amid Strong Market Performance

2025-10-20 17:48:09

Labcorp Holdings, Inc. has recently adjusted its valuation, with its current price at $285.94. The company has shown strong performance over the past year, achieving a 32.91% return, significantly outperforming the S&P 500. Key financial metrics indicate Labcorp's competitive positioning within the Pharmaceuticals & Biotechnology sector.

Labcorp Holdings, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance

2025-10-20 15:34:51

Labcorp Holdings, Inc. has recently revised its evaluation amid current market dynamics. The stock has shown strong performance over the past year, significantly outperforming the S&P 500. Technical indicators present mixed signals, with bullish trends in some areas and bearish indicators in others, reflecting a complex market environment.

Is Labcorp Holdings, Inc. overvalued or undervalued?

2025-10-20 12:31:46

As of 17 October 2025, the valuation grade for Labcorp Holdings, Inc. has moved from expensive to fair. The company is currently fairly valued based on its metrics. Key ratios include a P/E ratio of 28.86, an EV to EBITDA of 14.80, and a PEG ratio of 0.0, indicating a lack of growth expectations priced into the stock. In comparison to peers, Labcorp's P/E ratio is notably higher than the industry average, suggesting that it is priced at a premium relative to its competitors. For instance, if we consider other companies in the Pharmaceuticals & Biotechnology sector, their P/E ratios may provide a clearer picture of relative valuation. Additionally, Labcorp has outperformed the S&P 500 over multiple periods, with a year-to-date return of 24.69% compared to the S&P 500's 13.30%, reinforcing the narrative of its fair valuation amidst strong performance....

Is Labcorp Holdings, Inc. overvalued or undervalued?

2025-10-19 12:08:45

As of 17 October 2025, the valuation grade for Labcorp Holdings, Inc. moved from expensive to fair. The company is currently fairly valued based on its metrics. Key ratios include a P/E ratio of 28.86, an EV to EBITDA of 14.80, and a PEG ratio of 0.0, indicating a lack of growth expectations priced into the stock. In comparison, peers such as Thermo Fisher Scientific have a P/E of 24.50, suggesting Labcorp's valuation is in line with industry standards. Labcorp has outperformed the S&P 500 with a year-to-date return of 24.69% compared to the S&P 500's 13.30%, reinforcing the notion that the stock is fairly valued given its recent performance....

Labcorp Holdings Hits New 52-Week High of $289.19

2025-10-02 22:45:41

Labcorp Holdings, Inc. achieved a new 52-week high of USD 289.19 on October 1, 2025, highlighting its strong position in the Pharmaceuticals & Biotechnology industry. The company has outperformed the S&P 500 over the past year, reflecting significant market momentum and robust financial metrics.

Labcorp Holdings Hits New 52-Week High at $288.24

2025-10-01 16:49:03

Labcorp Holdings, Inc. achieved a new 52-week high of USD 288.24 on September 30, 2025, highlighting its strong position in the Pharmaceuticals & Biotechnology sector. The company has shown resilience over the past year, with significant stock performance and ongoing engagement in the competitive market landscape.

Is Labcorp Holdings, Inc. technically bullish or bearish?

2025-09-20 20:32:53

As of 1 October 2023, the technical stance for Labcorp Holdings, Inc. is bullish overall, with a strong bullish signal from the MACD on both weekly and monthly time frames. The daily moving averages also indicate bullish momentum. Additionally, the Bollinger Bands and OBV show mildly bullish trends on both weekly and monthly periods. However, Dow Theory suggests a mildly bearish stance on the monthly timeframe, indicating some caution. In terms of performance, Labcorp has outperformed the S&P 500 year-to-date with a return of 20.86% compared to the S&P 500's 12.22%, and over the past year, it has also outperformed with a return of 21.97% versus 17.14%. Overall, the bullish indicators suggest a positive outlook despite some mixed signals in the longer-term trends....

Is Labcorp Holdings, Inc. overvalued or undervalued?

2025-09-20 18:50:37

As of 6 February 2025, the valuation grade for Labcorp Holdings, Inc. has moved from expensive to fair, indicating a more favorable assessment of its market position. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 28.86, an EV/EBITDA of 14.80, and a PEG ratio of 0.0. In comparison, its peers in the Pharmaceuticals & Biotechnology industry exhibit varying valuations, but Labcorp's P/E ratio aligns closely with industry standards, suggesting it is competitively positioned. In terms of recent performance, Labcorp has outperformed the S&P 500 year-to-date with a return of 20.86% compared to the index's 12.22%, although it lags behind the S&P 500 over longer periods, such as the last three and five years. This mixed performance reinforces the notion that while the company is currently fairly valued, its long-term growth may need to be closely monitored against broader ...

View All News